Related coverage linked through entity extraction aliases.
May 31, 2026
BioNTech presented phase 2 data for HER2-directed ADC Trastuzumab Pamirtecan showing 47.9% response rate in endometrial cancer, with FDA submission planned for 2026. BioLineRx dosed first patient in phase 1/2a GLIX1 trial for glioblastoma and reported new preclinical data. Both companies presented at ASCO 2026.
Mar 20, 2026
Northwestern University researchers found that levetiracetam, an FDA-approved anti-seizure medication, prevents formation of toxic amyloid-beta 42 peptides in the brain, offering a potential strategy for early Alzheimer's prevention.
Mar 18, 2026
Researchers have developed advanced platforms to study human neural networks, including 3D bioelectronics for brain organoids and scalable 2D neuron networks that reveal brain-like rhythms and drug responses.
Feb 13, 2026
Scientists at Northwestern University developed human spinal cord organoids that accurately replicate injury responses including cell death, inflammation, and glial scarring. Testing showed a "dancing molecules" therapy significantly reduced scarring and promoted nerve regrowth.
